Literature DB >> 20652216

[PET/CT for diagnostics and therapy stratification of lung cancer].

C Kratochwil1, U Haberkorn, F L Giesel.   

Abstract

With the introduction of positron emission tomography (PET) and more recently the hybrid systems PET/CT, the management of cancer patients in the treatment strategy has changed tremendously. The combination of PET with multidetector CT scanning enables the integration of metabolic and high resolution morphological image information. PET/CT is nowadays an established modality for tumor detection, characterization, staging and response monitoring. The increased installation of PET/CT systems worldwide and also the increased scientific publications underline the importance of this imaging modality. PET/CT is particular the imaging modality of choice in lung cancer staging and re-staging (T, N and M staging). The possible increased success of surgery in lung cancer patients and also the expected reduction in additional invasive diagnostics lead to benefits for both the individual patient and the healthcare system. In this review article PET and PET/CT is presented for diagnostic and therapeutic stratification in lung cancer. The fundamentals of glucose metabolism, staging, tumor recurrence and therapeutic monitoring are presented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652216     DOI: 10.1007/s00117-009-1960-6

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  50 in total

1.  Clinical relevance of imaging proliferative activity in lung nodules.

Authors:  Andreas K Buck; Martin Hetzel; Holger Schirrmeister; Gisela Halter; Peter Möller; Clemens Kratochwil; Andreas Wahl; Gerhard Glatting; Felix M Mottaghy; Torsten Mattfeldt; Bernd Neumaier; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-14       Impact factor: 9.236

2.  Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.

Authors:  T Bury; J L Corhay; B Duysinx; F Daenen; B Ghaye; N Barthelemy; P Rigo; P Bartsch
Journal:  Eur Respir J       Date:  1999-12       Impact factor: 16.671

3.  Comparison of CT histogram analysis and chemical shift MRI in the characterization of indeterminate adrenal nodules.

Authors:  Kartik S Jhaveri; Fenella Wong; Sangeet Ghai; Masoom A Haider
Journal:  AJR Am J Roentgenol       Date:  2006-11       Impact factor: 3.959

4.  Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT.

Authors:  S Pauls; A K Buck; K Hohl; G Halter; M Hetzel; N M Blumstein; F M Mottaghy; G Glatting; S Krüger; L Sunder-Plassmann; P Möller; V Hombach; H-J Brambs; S N Reske
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379

5.  Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.

Authors:  Claude Nahmias; Wahid T Hanna; Lindi M Wahl; Misty J Long; Karl F Hubner; David W Townsend
Journal:  J Nucl Med       Date:  2007-05       Impact factor: 10.057

6.  Respiratory gating enhances imaging of pulmonary nodules and measurement of tracer uptake in FDG PET/CT.

Authors:  Matthias K Werner; J Anthony Parker; Gerald M Kolodny; Jeffrey R English; Matthew R Palmer
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

7.  PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.

Authors:  Zohar Keidar; Nissim Haim; Luda Guralnik; Mirjana Wollner; Rachel Bar-Shalom; Alon Ben-Nun; Ora Israel
Journal:  J Nucl Med       Date:  2004-10       Impact factor: 10.057

Review 8.  Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.

Authors:  Rodney J Hicks
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

9.  Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer.

Authors:  Wenfeng Yang; Zheng Fu; Jinming Yu; Shuanghu Yuan; Baijiang Zhang; Daotang Li; Ligang Xing; Dongbo Zhao; Dianbin Mu; Xiaorong Sun; Yufang Fang; Yong Huang; Yong Huange; Wanhu Li
Journal:  Lung Cancer       Date:  2008-01-04       Impact factor: 5.705

10.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

View more
  8 in total

1.  Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer.

Authors:  Paul Flechsig; Peter Choyke; Clemens Kratochwil; Arne Warth; Gerald Antoch; Tim Holland Letz; Daniel Rath; Viktoria Eichwald; Peter E Huber; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

2.  Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients.

Authors:  Paul Flechsig; Philipp Frank; Clemens Kratochwil; Gerald Antoch; Daniel Rath; Jan Moltz; Michael Rieser; Arne Warth; Hans-Ulrich Kauczor; Lawrence H Schwartz; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

3.  Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis.

Authors:  Paul Flechsig; Ramin Rastgoo; Clemens Kratochwil; Ole Martin; Tim Holland-Letz; Alexander Harms; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

4.  [Lung cancer staging].

Authors:  C Hintze; J Dinkel; J Biederer; C P Heussel; M Puderbach
Journal:  Radiologe       Date:  2011-02       Impact factor: 0.635

Review 5.  Post-therapeutic positron emission tomography/computed tomography for early detection of non-small cell lung cancer recurrence.

Authors:  Sonja Sudarski; Thomas Henzler; Stefan O Schoenberg
Journal:  Transl Lung Cancer Res       Date:  2013-08

6.  A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model.

Authors:  Paul Flechsig; Clemens Kratochwil; Arne Warth; Daniel Rath; Viktoria Eichwald; Peter E Huber; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

7.  Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD.

Authors:  Paul Flechsig; Olena Hural; Michael Kreuter; Martin Eichhorn; Gudula HEUßEL; Christos Sachpekidis; Hans-Ulrich Kauczor; Uwe Haberkorn; Claus Peter Heussel; Monika Eichinger
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

8.  Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients.

Authors:  Bernd Schmidt; Julia Beyer; Dimo Dietrich; Ines Bork; Volker Liebenberg; Michael Fleischhacker
Journal:  PLoS One       Date:  2015-02-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.